Article
Respiratory System
Rudolf M. Huber, Diego Kauffmann-Guerrero, Hans Hoffmann, Michael Flentje
Summary: Recent developments in the treatment of locally advanced nonsmall cell lung cancer have focused on integrating immunotherapy with radiotherapy, chemotherapy, and adjuvant targeted therapy. The importance of consolidation therapy, pathological evaluation, and investigation of immunological features and driver mutations in improving management and prognosis has been emphasized.
EUROPEAN RESPIRATORY REVIEW
(2021)
Article
Biochemistry & Molecular Biology
Si-Yang Maggie Liu, Hai-Yan Tu, Xue-Wu Wei, Hong-Hong Yan, Xiao-Rong Dong, Jiu-Wei Cui, Zhen Zhou, Chong-Rui Xu, Ming-Ying Zheng, Yang-Si Li, Zhen Wang, Xiao-Yan Bai, An-Na Li, Yue-Li Sun, Jie Huang, Jia-Xin Lin, E. E. Ke, Bing-Fei Xu, Chang Lu, Yingying Du, Yuan Chen, Rui Ma, Bu-Hai Wang, Shun-Dong Cang, Bin-Chao Wang, Hua-Jun Chen, Jin-Ji Yang, Yangqiu Li, Qing Zhou, Yi-Long Wu
Summary: In this study, a phase 2 adaptive umbrella trial and a real-world study were conducted to explore targeted treatments for non-small-cell lung cancer patients with rare genetic mutations. The results showed that the objective response rates for the criteria-fulfilled and compassionate use cohorts treated with the pan-HER receptor tyrosine kinase inhibitor pyrotinib were 35.7% and 16.7% respectively, while the disease control rate for the compassionate use cohort was 83.4%.
Review
Oncology
Selina K. Wong, Wade T. Iams
Summary: The use of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of small-cell lung cancer (SCLC) by providing significant survival benefit. Current trials are exploring the application of ICIs in the limited-stage setting in combination with chemoradiation or as adjuvant treatment post-chemoradiation. Multiple trials have established the combination of first-line ICIs and chemotherapy as the new standard of care for extensive-stage SCLC.
Review
Pharmacology & Pharmacy
Zi-Xian Liao, Ivan M. Kempson, Chia-Chen Hsieh, S-Ja Tseng, Pan-Chyr Yang
Summary: The presence of lactate and its relationship with drug resistance and genetic mutations in NSCLC highlights the potential for improving therapeutic outcomes by enzymatically lowering lactate levels. Targeting lactate may promote an oncolytic immune microenvironment within the tumor, offering a promising approach for enhancing NSCLC treatment efficacy.
DRUG DISCOVERY TODAY
(2021)
Article
Respiratory System
Kohei Otsubo, Junji Kishimoto, Masahiko Ando, Hirotsugu Kenmotsu, Yuji Minegishi, Hidehito Horinouchi, Terufumi Kato, Eiki Ichihara, Masashi Kondo, Shinji Atagi, Motohiro Tamiya, Satoshi Ikeda, Toshiyuki Harada, Shinnosuke Takemoto, Hidetoshi Hayashi, Keita Nakatomi, Yuichiro Kimura, Yasuhiro Kondoh, Masahiko Kusumoto, Kazuya Ichikado, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Yoichi Nakanishi, Isamu Okamoto
Summary: This study evaluated the efficacy and safety of nintedanib plus chemotherapy compared with chemotherapy alone in advanced NSCLC patients with IPF. The primary end-point of exacerbation-free survival was not achieved, but nintedanib combined with chemotherapy improved overall survival in patients with nonsquamous histology.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Review
Medical Laboratory Technology
Lea Sinoquet, William Jacot, Xavier Quantin, Catherine Alix-Panabieres
Summary: This study discusses the application of immune checkpoint inhibitors in the treatment of metastatic nonsmall cell lung cancer and focuses on the evaluation of blood biomarkers such as circulating cell-free DNA, circulating tumor DNA, blood tumor mutational burden, and circulating tumor cells. Monitoring these biomarkers during immunotherapy may assist clinicians in making therapeutic decisions.
CLINICAL CHEMISTRY
(2023)
Review
Oncology
Martin Reck, Jordi Remon, Matthew D. Hellmann
Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Brittney Chau, Philip H. G. Ituarte, Ashwin Shinde, Richard Li, Jessica Vazquez, Scott Glaser, Erminia Massarelli, Ravi Salgia, Loretta Erhunmwunsee, Kimlin Ashing, Arya Amini
Summary: The study found that foreign-born NSCLC patients in California have a lower risk of mortality compared to native-born patients after adjusting for treatments received and socioeconomic factors.
Review
Oncology
Jon Zugazagoitia, Luis Paz-Ares
Summary: Extensive-stage small-cell lung cancer is a challenging disease to treat, and despite improvements in first-line therapy, resistance remains a significant issue. Recent progress in understanding the molecular biology of SCLC holds potential for molecularly informed therapeutic strategies for patients with SCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Kit Yee Wong, Alvin Ho-Kwan Cheung, Bonan Chen, Wai Nok Chan, Jun Yu, Kwok Wai Lo, Wei Kang, Ka Fai To
Summary: Lung cancer is a common and deadly disease, with the tumor microenvironment playing a crucial role. Cancer-associated fibroblasts (CAFs) have gained attention in the study of nonsmall cell lung carcinoma (NSCLC), as their heterogeneity and functions are closely associated with tumor development.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Respiratory System
Rolof G. P. Gijtenbeek, Vincent van der Noort, Joachim G. J. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D. J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E. E. M. van den Borne, Harry J. M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken
Summary: This study found that in patients with EGFR-mutated NSCLC, intercalated erlotinib with cisplatin-pemetrexed chemotherapy significantly prolonged progression-free survival compared to erlotinib monotherapy, but at the cost of increased toxicity.
Article
Chemistry, Multidisciplinary
Elham Hatami, Prashanth K. B. Nagesh, Mohammed Sikander, Anupam Dhasmana, Subhash C. Chauhan, Meena Jaggi, Murali M. Yallapu
Summary: The study demonstrates that Tannic acid (TA) has antiproliferative and antiangiogenic effects against nonsmall-cell lung cancer (NSCLC).
Article
Cell & Tissue Engineering
Yuehong Wang, Yuman Yu, Weijun Yang, Linying Wu, Yaoshun Yang, Qianyun Lu, Jianying Zhou
Summary: Increasing evidence suggests that quiescent cancer stem cells (CSCs) are responsible for chemoresistance. SETD4, a protein containing SET domain, epigenetically regulates cell quiescence in breast cancer stem cells (BCSCs), resulting in chemoradioresistance. However, the role of SETD4 in chemoresistance, tumor progression, and prognosis in nonsmall cell lung cancer (NSCLC) patients remains unclear.
STEM CELLS INTERNATIONAL
(2023)
Article
Oncology
Suresh S. Ramalingam, Eddie Thara, Mark M. Awad, Afshin Dowlati, Basir Haque, Thomas E. Stinchcombe, Grace K. Dy, David R. Spigel, Sharon Lu, Nithya Iyer Singh, Yongqiang Tang, Iryna Teslenko, Nicholas Iannotti
Summary: The combination of niraparib and pembrolizumab showed promising clinical activity in patients with advanced and/or metastatic NSCLC, with significant objective response rates observed in patients with high levels of PD-L1 expression. This combination therapy also demonstrated manageable safety profiles consistent with the known side effects of each drug individually, supporting further investigation into its potential as a treatment option.
Review
Medicine, General & Internal
Ruby Gupta, Melanie Smalley, Nwabundo Anusim, Vishal Jindal, Mandeep Singh Rahi, Sorab Gupta, Sachin Gupta, Ishmael Jaiyesimi
Summary: Recent advancements in diagnostic approach and management strategies have shifted the treatment of metastatic NSCLC from primarily chemotherapy to more targeted therapies and immune checkpoint inhibitors, leading to better survival rates and reduced toxicity.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
(2021)
Article
Oncology
Dirk Rades, Michael Hueppe, Steven E. Schild
Letter
Oncology
Steven E. Schild, Sameer R. Keole, Robert L. Foote
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2013)
Article
Oncology
Grace K. Dy, Sumithra J. Mandrekar, Garth D. Nelson, Jeffrey P. Meyers, Araba A. Adjei, Helen J. Ross, Rafat H. Ansari, Alan P. Lyss, Philip J. Stella, Steven E. Schild, Julian R. Molina, Alex A. Adjei
JOURNAL OF THORACIC ONCOLOGY
(2013)
Article
Oncology
Joseph K. Salama, Lydia Hodgson, Herbert Pang, James J. Urbanic, A. William Blackstock, Steven E. Schild, Jeffrey Crawford, Jeffrey A. Bogart, Everett E. Vokes
JOURNAL OF THORACIC ONCOLOGY
(2013)
Article
Urology & Nephrology
Sujay A. Vora, William W. Wong, Steven E. Schild, Gary A. Ezzell, Paul E. Andrews, Robert G. Ferrigni, Scott K. Swanson
JOURNAL OF UROLOGY
(2013)
Article
Oncology
Audrey Mauguen, Jean-Pierre Pignon, Sarah Burdett, Caroline Domerg, David Fisher, Rebecca Paulus, Samithra J. Mandrekar, Chandra P. Belani, Frances A. Shepherd, Tim Eisen, Herbert Pang, Laurence Collette, William T. Sause, Suzanne E. Dahlberg, Jeffrey Crawford, Mary O'Brien, Steven E. Schild, Mahesh Parmar, Jayne F. Tierney, Cecile Le Pechoux, Stefan Michiels
Article
Oncology
Dirk Rades, Liesa Dziggel, Viorica Nagy, Barbara Segedin, Radka Lohynska, Theo Veninga, Mai T. Khoa, Ngo T. Trang, Steven E. Schild
RADIOTHERAPY AND ONCOLOGY
(2013)
Article
Oncology
L. Dziggel, B. Segedin, N. H. Podvrsnik, I. Oblak, S. E. Schild, D. Rades
STRAHLENTHERAPIE UND ONKOLOGIE
(2013)
Review
Oncology
Ronald Chow, Peter Hoskin, Steven E. Schild, Srinivas Raman, James Im, Daniel Zhang, Stephanie Chan, Nicholas Chiu, Leonard Chiu, Henry Lam, Edward Chow, Michael Lock
RADIOTHERAPY AND ONCOLOGY
(2019)
Article
Oncology
Daniel F. Craft, Jarrod Lentz, Mike Armstrong, Madeline Foster, Justin Gagneur, Daniel Harrington, Steven E. Schild, Mirek Fatyga
PRACTICAL RADIATION ONCOLOGY
(2020)
Correction
Oncology
Ronald Chow, Peter Hoskin, Steven E. Schild, Srinivas Raman, James Im, Daniel Zhang, Stephanie Chan, Nicholas Chiu, Leonard Chiu, Henry Lam, Edward Chow, Michael Lock
RADIOTHERAPY AND ONCOLOGY
(2020)
Article
Oncology
Steven E. Schild, Xiaofei Wang, Christine M. Bestvina, Terence Williams, Greg Masters, Anurag K. Singh, Thomas E. Stinchcombe, Joseph K. Salama, Steven Wolf, Tyler Zemla, Narjust Duma, Stephen G. Chun, Arya Amini, David Kozono, Colleen Watt
Summary: This study aims to determine if stereotactic body radiation therapy (SBRT) added to systemic therapy can significantly improve outcomes for patients with advanced stage non-small cell lung cancer (NSCLC) without PD-L1 protein expression. The trial will compare SBRT plus systemic therapy with systemic therapy alone and evaluate progression-free and overall survival. This multi-institutional trial will provide further insight into the efficacy of combining SBRT with systemic therapy.
CLINICAL LUNG CANCER
(2022)
Review
Oncology
R. S. Bhangoo, T. W. Cheng, M. M. Petersen, C. S. Thorpe, T. A. DeWees, J. D. Anderson, C. E. Vargas, S. H. Patel, M. Y. Halyard, S. E. Schild, W. W. Wong
Summary: This article characterizes radiation recall dermatitis (RRD), a skin reaction triggered by subsequent systemic therapy, and compares the most common drug classes implicated in this phenomenon.
SEMINARS IN ONCOLOGY
(2022)
Article
Biology
Dirk Rades, Cansu Delikanli, Steven E. Schild, Charlotte Kristiansen, Soren Tvilsted, Stefan Janssen
Summary: Decisions regarding personalized treatment for brain metastases should consider the patient's estimated lifespan, which can be determined using survival scores. In a study of very elderly patients (>= 80 years) with brain metastases who underwent whole-brain radiotherapy, a new survival score showed higher accuracy in predicting death and survival compared to an existing tool. The new score appears to be preferable, but further validation is needed.
Article
Oncology
William W. Wong, Eric M. Anderson, Homan Mohammadi, Thomas B. Daniels, Steve E. Schild, Sameer R. Keole, C. Richard Choo, Katherine S. Tzou, Alan H. Bryce, Thai H. Ho, Fernando J. Quevedo, Sujay A. Vora
CLINICAL GENITOURINARY CANCER
(2017)